<DOC>
	<DOCNO>NCT02463539</DOCNO>
	<brief_summary>Descriptive study residual anti-pneumococcal immunity patient Anti-neutrophil cytoplasmic antibody ( ANCA ) -associated vasculitis ( AAV ) previously go pneumococcal immunization .</brief_summary>
	<brief_title>Residual Anti-pneumococcal Immunity After Pneumococcal Immunization ANCA-associated Vasculitis</brief_title>
	<detailed_description>The purpose study determine , serotype-specific enzyme link immunosorbent assay ( ELISA ) opsonophagocytosis ( OPA ) titres whether AAV patient go pneumococcal vaccination protect invasive pneumococcal disease ( IPD ) .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age â‰¥ 18 year Antineutrophil cytoplasmic antibody ( ANCA ) associate vasculitis : diagnosis granulomatosis polyangiitis , microscopic polyangiitis eosinophilic granulomatosis polyangiitis accord American College Rheumatology criterion Antipneumococcal immunization past 36 month History antipneumococcal vaccination accord French recommendation ( simple vaccine schedule PPV23 combine vaccine schedule PCV13 follow PPV23 8 week later ) Known suspect pregnancy Splenectomy Patient without social security coverage Patient opposal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pneumococcal infection</keyword>
	<keyword>Invasive pneumococcal disease ( IPD )</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Systemic vasculitis</keyword>
	<keyword>ANCA-associated vasculitis</keyword>
	<keyword>Vaccinology</keyword>
	<keyword>Immunocompromised</keyword>
	<keyword>Auto-immune disease</keyword>
</DOC>